Monitoring peri-operative immune suppression in renal cancer patients

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1455-1464

  Hase, Sabine ^a   Weinitschke, Kristin ^a   Fischer, Kirsten ^a   Fornara, Paolo ^a   Hoda, Raschid ^a   Unverzagt, Susanne ^a   Seliger, Barbara ^a   Riemann, Dagmar ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Aminopeptidase N CD13; Cytometry; HLA DR; Immune monitoring; Renal cancer

Indexed keywords

CD28 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; INNATE IMMUNITY; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LEUKOCYTE COUNT; MALE; NATURAL KILLER CELL; PATIENT MONITORING; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PERIOPERATIVE PERIOD;

EID: 79953045942     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1199     Document Type: Article

References (38)

1. Saylor PJ and Michaelson MD: New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Cancer Netw 7: 645-656, 2009.
2. Facchini G, Perri F, Caraglia M, et al: New treatment approaches in renal cell carcinoma. Anticancer Drugs 20: 893-900, 2009.
3. Downs TM, Schultzel M, Shi H, Sanders C, Tahir Z and Sadler GR: Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients. Crit Rev Oncol Hematol 70: 59-70, 2009.
4. Donskov F and von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24: 1997-2005, 2006.
5. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24: 1169-1177, 2006. (Pubitemid 46638815)
6. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL and Hawkins RE: Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 56: 1743-1753, 2007. (Pubitemid 47313079)
7. Kusmartsev S, Su Z, Heiser A, et al: Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14: 8270-8278, 2008.
8. Ni Choileain N and Redmond HP: Cell response to surgery. Arch Surg 141: 1132-1140, 2006.
9. Ljungberg B, Cowan NC, Hanbury DC, et al: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398-406, 2010.
10. Nicholson ML, Kaushik M, Lewis GR, et al: Randomized clinical trial of laparoscopic versus open donor nephrectomy. Br J Surg 97: 21-28, 2010.
11. Porta C, Bonomi L, Lillaz B, et al: Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res 27: 165-173, 2007.
12. Böhm M, Ittenson A, Philipp C, Röhl FW, Ansorge S and Allhoff EP: Complex peri-operative immuno-dysfunction in patients with renal cell carcinoma. J Urol 66: 831-836, 2001. (Pubitemid 32750958)
13. Choueiri TK, Garcia JA, Elson P, et al: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110: 543-550, 2007. (Pubitemid 47106142)
14. Wilcox RA: Cancer-associated mycloproliferation: old association, new therapeutic target. Mayo Clin Proc 85: 656-663, 2010.
15. Ochoa AC, Zea AH, Hernandez C and Rodriguez PC: Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13: S721-S726, 2007.
16. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R and Ochoa AC: Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69: 1553-1560, 2009.
17. Ardi VC, Kupriyanova TA, Deryugina EI and Quigley JP: Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104: 20262-20267, 2007.
18. + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 14: 5884-5892, 2008.
19. Dzionek A, Fuchs A, Schmidt P, et al: BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165: 6037-6046, 2000.
20. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 207: 1247-1260, 2010.
21. Döcke WD, Höflich C, Davis KA, et al: Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 51: 2341-2347, 2005. (Pubitemid 41692579)
22. Thibodeau J, Bourgeois-Daigneault MC, Huppe G, et al: Interleukin-10-induced MARCHl mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol 38: 1225-1230, 2008.
23. Huschak G, Zur Nieden K, Stuttmann R and Riemann D: Changes in monocytic expression of aminopeptidase N/CD13 after major trauma. Clin Exp Immunol 134: 491-496, 2003. (Pubitemid 37542090)
24. van Hal PT, Hopstaken-Broos JP, Prins A, et al: Potential indirect anti-inflammatory effects of IL-4. Stimulation of human monocytes, macrophages, and endothelial cells by IL-4 increases aminopeptidase-N activity (CD13; EC 3.4.11.2). J Immunol 153: 2718-2728, 1994. (Pubitemid 24278141)
25. Kehlen A, Geisler M, Olsen J, Sablotzki A, Langner J and Riemann D: IL-10 and TGF-beta differ in their regulation of aminopeptidase N/CD13 expression in monocytes. Int J Mol Med 13: 877-882, 2004.
26. Junker U, Haufe CC, Nuske K, et al: Elevated plasma TGF-beta1 in renal diseases: cause or consequence? Cytokine 12: 1084-1091, 2000.
27. Navarrete Santos A, Kehlen A, Schütte W, Langner J and Riemann D: Regulation by transforming growth factor-beta1 of class II mRNA and protein expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int Immunol 10: 601-607, 1998. (Pubitemid 28221461)
28. Riemann D, Kehlen A and Langner J: CD13 - not just a marker in leukemia typing. Immunol Today 20: 83-88, 1999. (Pubitemid 29136633)
29. Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic interventions. Semin Cancer Biol 16: 3-15, 2006.
30. Whiteside TL: Immune responses to malignancies. J Allergy Clin Immunol 125 (2 Suppl. 2): S272-S283, 2010.
31. Qin S, Rottman JB, Myers P, et al: The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101: 746-754, 1998. (Pubitemid 28096070)
32. Tarazona R, DelaRosa O, Alonso C, et al: Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 121: 77-88, 2000. (Pubitemid 32115402)
33. + lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22: 3679-3683, 2002. (Pubitemid 36132849)
34. Greenwald RJ, Freeman GJ and Sharpe AH: The B7 family revisited. Annu Rev Immunol 23: 515-548, 2005.
35. Sharpe AH, Wherry EJ, Ahmed R and Freeman GJ: The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8: 239-245, 2007. (Pubitemid 46745373)
36. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC and Kwon ED: PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13: 1757-1761, 2007. (Pubitemid 46952942)
37. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH and Flavell RA: ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409: 97-101, 2001. (Pubitemid 32098632)
38. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL and Hawkins RE: Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 56: 1743-1753, 2007. (Pubitemid 47313079)